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Extracellular calcium is essential for life and its concentration in the blood is maintained
within a narrow range. This is achieved by a feedback loop that receives input from
the calcium-sensing receptor (CASR), expressed on the surface of parathyroid cells.
In response to low ionized calcium, the parathyroids increase secretion of parathyroid
hormone (PTH) which increases serum calcium. The CASR is also highly expressed
in the kidneys, where it regulates the reabsorption of calcium from the primary filtrate.
Autosomal dominant hypocalcemia (ADH) type 1 is caused by heterozygous activating
mutations in the CASR which increase the sensitivity of the CASR to extracellular ionized
calcium. Consequently, PTH synthesis and secretion are suppressed at normal ionized
calcium concentrations. Patients present with hypocalcemia, hyperphosphatemia, low
magnesium levels, and low or low-normal levels of PTH. Urinary calcium excretion is
typically increased due to the decrease in circulating PTH concentrations and by the
activation of the renal tubular CASR. Therapeutic attempts using CASR antagonists
(calcilytics) to treat ADH are currently under investigation. Recently, heterozygous
mutations in the alpha subunit of the G protein G11 (Gα11) have been identified in
patients with ADH, and this has been classified as ADH type 2. ADH2 mutations lead to
a gain-of-function of Gα11, a key mediator of CASR signaling. Therefore, the mechanism
of hypocalcemia appears similar to that of activating mutations in the CASR, namely an
increase in the sensitivity of parathyroid cells to extracellular ionized calcium. Studies of
activating mutations in the CASR and gain-of-function mutations in Gα11 can help define
new drug targets and improve medical management of patients with ADH types 1 and 2.
Keywords: autosomal-dominant hypocalcemia, CASR, calcium metabolism, GNA11, G11, calcilytics, YM254890,
hypocalcemia
PHYSIOLOGY OF EXTRACELLULAR CALCIUM HOMEOSTASIS
Calcium is vital for many functions of the body and blood calcium concentrations must be
maintained within a narrow physiological range of 8.5–10.5 mg/dl (2.12–2.62 mmol/L). The
calcium-sensing receptor (CASR), a class C G-protein coupled receptor comprised of 1078
amino acids, is an integral component of the homeostatic system that controls blood calcium
concentrations (Hofer and Brown, 2003). In humans, the twomajor calcium-controlling hormones
that maintain serum calcium within the normal range are parathyroid hormone (PTH) and
1,25-dihydroxyvitamin D. PTH is produced and secreted by the parathyroid glands, which
sense extracellular calcium through the calcium sensing receptor, located on the surface of the
parathyroid chief cells (Brown et al., 1993).
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When serum ionized calcium is low, increased amounts of
PTH are secreted into the circulation; PTH acts mainly on kidney
and bone, through binding and activating the PTH/PTHrP
receptor, to increase serum ionized calcium. In bone, PTH
induces osteoblasts to trigger osteoclasts to release calcium and
phosphorous into the circulation, and it stimulates osteocytic
osteolysis (Tazawa et al., 2004). In addition, PTH acts at the
distal tubules of the kidneys to induce calcium reabsorption.
In the proximal tubule, PTH inhibits phosphate reabsorption
from the urine resulting in a decrease in serum phosphate levels.
PTH also activates the 1α-hydroxylase enzyme (CYP27B1) in
the renal proximal tubule, which converts 25-hydroxyvitamin
D to the active form, 1,25-dihydroxyvitamin D, or calcitriol.
This active vitamin D functions in the intestine to increase the
absorption of calcium (and phosphate) from the gut. Taken
together, these concerted actions of PTH mobilize calcium in
an effort to restore the serum calcium to the above-mentioned
normal range.
CASR AND PARATHYROID CELLS
The calcium sensing receptor is expressed in most tissues (Brown
et al., 1993). However, the highest levels of its expression
are found in the parathyroid glands and in the kidneys. The
minute-to-minute tight regulation of calcium is achieved through
the ability of the CASR to sense minor changes in extracellular
calcium. The relationship between PTH secretion and the
extracellular calcium concentration has been described as a steep
sigmoidal curve. In the parathyroid cell, activation of the CASR
by extracellular ionized calcium stimulates intracellular signal
transduction pathways, resulting in an increase in intracellular
calcium (nM range), that ultimately leads to an inhibition of PTH
production and secretion. This is in stark contrast to the usual
signaling pattern of intracellular calcium, which is characterized
by the stimulation of hormone production and secretion in
response to an increase in intracellular calcium. The mechanism
for this peculiar opposite effect in the parathyroids is unknown.
Several signaling pathways downstream of the CASR are
engaged in the parathyroid cell. In the presence of ligand, the
CASR activates Gq and G11(Hofer and Brown, 2003), leading
to a stimulation of phospholipase C (PLC). PLC hydrolyzes
phosphatidylinositol 4,5-bisphosphate (PIP2) to diacyl glycerol
and inositol 1,4,5-trisphosphate (IP3), which in turn causes
activation of protein kinase C (PKC) and release of intracellular
calcium, respectively. The CASR also couples to the G-protein
Gi, which inhibits adenylate cyclase and leads to a reduction in
intracellular cAMP.
In addition to extracellular calcium, the parathyroids also
respond to phosphate, 1,25-dihydroxyvitamin D, and FGF23,
both directly and indirectly, to modulate PTH secretion (Naveh-
Many et al., 2002; Silver and Naveh-Many, 2009).
CASR AND THE KIDNEYS
In the kidney, the CASR is highly expressed in the basolateral
membrane of the thick ascending limb (TAL; Loupy et al., 2012;
Toka et al., 2012; Crisi et al., 2013). While there is conflicting
evidence for the expression of CASR mRNA and protein in
other parts of the nephron, functional studies suggest that it
is more widely expressed. For example, in the collecting duct,
CASR activation leads to urine acidification and a reduction in
water reabsorption, which could reduce the risk of kidney stone
formation (Renkema et al., 2009).
In the TAL, calcium is reabsorbed passively along the
paracellular pathway, driven by luminal electropositivity, which
is dependent on the rate and extent of NaCl reabsorption.
In the apical membrane of the TAL, Na+, 2Cl−, and K+ are
electroneutrally transported into the cell. K+ is recycled back into
the lumen through the apical ROMK channel leading to lumen
positivity, the main driver of paracellular calcium transport from
the lumen into the TAL. In the distal convoluted tubule (DCT),
calcium is reabsorbed through an active transcellular transport.
Calcium enters the DCT through TRPV5 and exits the cell via
the sodium-calcium exchanger 1 (Riccardi and Valenti, 2016).
Activation of the CASR in the kidney leads to a decrease in
calcium (and water and sodium) reabsorption. While these exact
pathways are not entirely elucidated, two potential mechanisms
have emerged. One involves the paracellular transport of calcium
from the lumen into the TAL, which is dependent on several
claudins, a family of proteins that establish barriers in tight
junctions. The CASR was discovered to control claudin-14
expression and therefore absorption of calcium through the
paracellular tight junctions (Gong and Hou, 2014). The second
possible mechanism is a reduction of the activity of the apical
K+ channel, which generates the lumen positivity. Patch clamp
studies showed that both calcium and neomycin are able to
reduce the activity of this potassium channel (Wang et al., 1996,
1997).
Investigators studying CASR knockout mouse models
demonstrated that the CASR also defends against hypercalcemia
by increasing calcium excretion by the kidney, independent of its
role in the parathyroid glands (Kantham et al., 2009).
AUTOSOMAL-DOMINANT
HYPOCALCEMIA TYPE 1
Key to the understanding of the role of the CASR in the
parathyroids was the discovery of mutations in the CASR gene
leading to human disease, and analysis of these mutations
in mouse models (Hannan and Thakker, 2013). Patients with
activating or inactivating germline mutations in the CASR
present with hypocalcemia or hypercalcemia, respectively.
Inactivating mutations of the CASR lead to familial hypocalciuric
hypercalcemia (FHH). The mirror image of FHH, autosomal-
dominant hypocalcemia (ADH) type 1, is caused by activating
mutations in the CASR and is the most common genetic
form of isolated hypoparathyroidism. These activating CASR
mutations lead to a leftward shift in the calcium-PTH curve
and therefore suppression of PTH secretion at physiological
levels of extracellular calcium. Biochemical hallmarks of
AHD1 are hypocalcemia, which is typically mild to moderate,
hyperphosphatemia, hypercalciuria, and inappropriately low
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but detectable PTH levels. Symptoms of ADH1 are caused
by hypocalcemia (mainly neuromuscular irritability) and are
typically mild.
In addition to this functional defect in the parathyroids,
activating CASR mutations have independent effects in the
kidneys. Therefore, patients with ADH1 have two mechanisms
contributing to hypercalciuria. First, low concentrations of
PTH, which normally induce reabsorption of calcium from
the primary filtrate, result in relative hypercalciuria. Second,
increased activation of the mutated CASR through extracellular
calcium in the distal renal tubules leads to evenmore pronounced
hypercalciuria for any given blood calcium level.
The presentation of the index case of kindred G (D’Souza-Li
et al., 2002) is typical for ADH1. Blood chemistries of this 21-year
old asymptomatic woman were tested because her three sisters
and her mother all had hypocalcemia. Her laboratory results
showed mild hypocalcemia (Ca = 7.5mg/dl, normal 8.5–10.5),
mild hyperphosphatemia (P = 4.8mg/dl, normal 2.6–4.5) and
hypomagnesemia (Mg = 1.4 mg/dl, normal 1.8–2.5), low but
detectable PTH (PTH= 16 pg/ml, normal 10–60) and an elevated
calcium/creatinine clearance ratio (0.088, normal< 0.02). Sanger
sequencing revealed a heterozygousmissensemutation leading to
the substitution of alanine to threonine in position 835, located in
the third extracellular loop of the CASR. In vitro studies using
HEK cells transfected with wildtype and mutant CASR cDNA
revealed the expected leftward shift in the calcium-response
curve (D’Souza-Li et al., 2002).
Diagnostic sequencing of the CASR gene is used to confirm
ADH1. More than 200 mutations of the CASR have been
reported, of which more than 70 are associated with ADH1,
the vast majority are heterozygous missense mutations
(www.casrdb.mcgill.ca). The CASR consists of three major
domains: the large extracellular domain (ECD), a transmembrane
domain (TMD), and an intracellular C-terminus. Many
mutations associated with ADH1 are located in the second
peptide loop of the ECD, which is predicted to be important for
dimer formation, as well as in the TMD 5 and 6 and in the region
of the third extracellular loop.
Clinical management of ADH1 is guided by the known high
risk for renal calcifications, kidney stones and kidney failure.
In asymptomatic patients, treatment should be avoided. When
hypocalcemic symptoms occur frequently enough to warrant
treatment, careful therapy with the lowest amount of calcium and
activated vitamin D is initiated. Goal calcium levels should be as
low as possible to alleviate symptoms. Thiazide diuretics, often
used in hypoparathyroidism because of their urinary calcium
lowering effect, have also been shown to be beneficial in ADH1
(Sato et al., 2002). In clinical studies in patients with ADH1,
once daily dosing of PTH(1–34) only corrected serum calcium
for a part of the day, and twice daily sc administration of PTH(1-
34) led to better control of blood calcium (Winer et al., 1998,
2008). However, PTH does not correct the effects of the activated
CASR in the kidneys, and indeed, urinary calcium excretion was
not normalized by PTH(1–34) injections. Studies of continuous
PTH(1–34) administration via pump therapy did normalize
urinary calcium in cases of postsurgical hypoparathyroidism
(Winer et al., 2012). Trials with PTH(1–84), which is an approved
treatment for other forms of hypoparathyroidism, excluded
patients with ADH1.
Small molecule allosteric modulators of the CASR have been
identified (Nemeth and Goodman, 2016). Positive modulators
(type II calcimimetics), such as cinacalcet, increase activation
of the CASR. Cinacalcet is primarily used for treatment
of patients with secondary hyperparathyroidism on dialysis.
Calcilytics, which are negative allosteric CASR modulators,
inhibit the activation of the CASR and therefore are of potential
interest for the treatment of ADH1. In cell culture experiments
studying activating CASRmutants, calcilytics have been shown to
normalize the leftward shift of the calcium response curve (Dong
et al., 2015; Hannan et al., 2015). The utility of calcilytics was
further demonstrated in two studies in mice harboring activating
CASR mutations. In one study, two knockin mouse models of
ADH1 with activating mutations in the CASR were generated.
Daily oral administration of the calcilytic JTT-305/MK-5442
to these mice was shown to increase PTH and calcium, and
to reduce urinary calcium excretion (Dong et al., 2015). A
second study using the Nuf mouse, another model of ADH1,
showed that intraperitoneal injection of the calcilytic NPS2143
transiently stimulated serum PTH secretion and increased serum
calcium without increasing urinary calcium (Hannan et al.,
2015). In a phase 2 clinical trial, IV administration of the
structurally closely related small molecule NPSP795 increased
plasma PTH levels and decreased the urinary fractional excretion
of calcium in five patients with ADH1 (Ramnitz et al., 2015).
In addition to a potential treatment for ADH1, calcilytics could
also have a role in reducing urinary excretion of calcium in
other patients with hypoparathyroidism, through blocking the
renal CASR.
AUTOSOMAL-DOMINANT
HYPOCALCEMIA TYPE 2
With the discovery that mutations in the gene encoding the alpha
subunit of the G protein G11 (GNA11) cause hypocalcemia, ADH
was divided into type 1, reviewed above, and type 2, caused
by activating mutations in GNA11. Patients with ADH2 present
with a wide range of hypocalcemic symptoms ranging from
paresthesias to tetany and seizures, or they can be asymptomatic.
The following describes the index case of Family A
(Mannstadt et al., 2013): A 15 year-old boy presented withmuscle
cramps and tremulousness. Past laboratory studies revealed
normal calcium at age 2. He experienced generalized seizures at
age 5 which were treated with carbamazepine for 1 year and did
not re-occur thereafter. Studies on presentation revealed mildly
low serum calcium, high phosphorous, and inappropriately low
PTH concentration (Table 1).
His mother, cousin, grandmother, and great-grandmother
were also affected with hypoparathyroidism revealing an
autosomal dominant inheritance pattern. Neither the patient nor
any of his family members had a history of mucocutaneous
candidiasis, hearing loss, renal abnormalities, or skin changes. He
was clinically diagnosed with ADH and genetic sequencing ruled
out mutations in the PTH and GCM2 genes, but also in CASR.
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TABLE 1 | Summary of the presenting laboratory values of the index case
of Family A, a 15 year-old boy with ADH2, from Mannstadt et al. (2013).
At presentation Normal range
Calcium (mM) 2.10 2.25–2.65
Phosphorous (mM) 2.30 0.90–1.70
PTH (pM) 1.2 1.2–5.5
Exome sequencing revealed a novel mutation in GNA11, which
was present only in affected family members (Mannstadt et al.,
2013).
Few patients have been described in the literature with ADH2,
limiting the number of observations (Table 2), but ADH2 might
have a slightly milder phenotype with respect to hypocalcemia
than patients with ADH1. Additionally, elevations in urinary
calcium of individuals with ADH2 appear to be less pronounced
than in those with activating CASR mutations in ADH1, raising
the question whether the CASR in the renal tubules couples to G
proteins other than G11.
The genetic basis of ADH2 was first elucidated by two groups.
One study focused on two large unrelated families counting a
total of 15 living patients with autosomal dominant isolated
hypoparathyroidism, in whom mutations in the genes encoding
the CASR, PTH, and GCM2 were ruled out (Mannstadt et al.,
2013). Affected individuals in both families were hypocalcemic
with inappropriately low PTH and elevated phosphorous. The
urinary calcium:creatinine ratio was found to be normal in all of
8 patients measured across both families. Genetic linkage analysis
revealed a linked interval of ∼10Mb on chromosome 19p13.3
with a maximal LOD score of 3.0. Among the approximately 50
genes that reside at this locus, GNA11 was a strong candidate
gene. Sanger sequencing discovered a heterozygous missense
mutation in GNA11 exon 2 (c.178C->T) changing the conserved
arginine 60 to a cysteine (p.Arg60Cys).Whole-exome sequencing
of two members of this family revealed that this R60C was
the only variant in the linked interval that was present in
both subjects. In the second family, exome sequencing of two
affected members uncovered a different mutation in GNA11,
a heterozygous missense mutation in exon 5. This mutation
(c.632C->G) leads to the substitution of the conserved serine
211 to a tryptophan (p.Ser211Trp). Analysis of exome data from
both families confirmed the absence of other variants affecting
the same gene in both families. Restriction site analysis of PCR
products revealed the presence of the respective mutation in
available affected members of each family, and the absence in
unaffected members (Mannstadt et al., 2013).
Investigators of the other study discovered inactivating
mutations in GNA11 associated with the mirror-image disease
FHH. They then hypothesized that activating mutations of
GNA11 could cause ADH (Nesbit et al., 2013). Eight unrelated
patients with hypocalcemia and low or inappropriately normal
PTH levels in the absence of CASR mutations were studied
by Sanger sequencing. In two ADH patients, mutations in
the GNA11 gene were uncovered. These patients had normal
magnesium levels, and normal urinary calcium to creatinine
clearance. The mutations were heterozygous missense mutations
in highly conserved residues, namely a G->A change at c.542
which predicts a protein change of Arg181Gln, and a C->G
change at c.1023 which causes the Phe341Leu change (Nesbit
et al., 2013).
Subsequently, additional mutations in GNA11 in other
families with ADH were published. In one large family,
whole-exome-sequencing revealed a heterozygous mutation
c.179G->T; p.R60L (Li et al., 2014). The affected individuals
in this family were reported to have short stature relative to
their unaffected family members. They also lacked hypercalciuria
and had normal serum magnesium levels, which contrasts with
patients with ADH1 (Li et al., 2014). A second large family
from Iran with ADH was studied by whole-exome sequencing
revealing a heterozygousmutation exon 7 ofGNA11 c1018G->A;
p.Val340Met (Piret et al., 2016). The Val340Met mutation was
also found in a family from Finland, in which all seven of
the family members studied had short stature and three had
intracranial calcifications (Tenhola et al., 2016).
In vitro studies of these GNA11 mutants using HEK293 cells
expressing the CASR have confirmed the hypothesis that they are
gain-of-function mutations. A leftward shift in the intracellular
calcium response curve to extracellular calcium was found,
indicating increased intracellular response to lesser amounts
of extracellular calcium in the setting of each mutant (Nesbit
et al., 2013; Li et al., 2014; Piret et al., 2016). Likewise, cells
expressing the R60L mutant demonstrated increased activation
of the SRE promoter and increased phosphorylation of ERK and
p38, downstream targets of G11/q signaling (Li et al., 2014).
In vitro studies using HEK293 cells have shown that the calcilytic
NPS2143, an allosteric modulator of the CASR, can rectify
impaired calcium signaling in ADH2 despite the fact that the
Gα11 protein is downstream of the CASR (Babinsky et al., 2016).
Molecular modeling has suggested different mechanisms
through which these mutations confer a gain of function in
Gα11 (Flock et al., 2015). The R60 residue (G.H1.9) is located
in the GTPase domain and has polar interactions with Asp71
(H.HA.3), which stabilize the interaction of the GTPase and
helical domain, thus stabilizing the GDP-bound inactive form of
Gα11. Replacement of the R60 residue is predicted to loosen the
tight clamshell leading to faster GDP-GTP exchange (Mannstadt
et al., 2013). Substitution of Ser211 (G.H2.2) with the bulky
tryptophan is predicted to disturb the interactions with the βγ
subunits (Mannstadt et al., 2013). The Arg181 (H.HF.6) residue
is located in the helical domain and forms hydrogen bonds
with residue R183 that is important for GTPase activity and
can confer oncogenic potential to G11 when mutated (Nesbit
et al., 2013). The Val340Met (G.H5.7) and Phe341Leu (G.H5.8)
mutations are located in the α5 helix of Gα11 therefore altering
the contacts between H5 and H1, which are important for Gα
subunit activation (Nesbit et al., 2013; Li et al., 2014).
To date, six mutations in GNA11 have been reported to cause
ADH2 (Mannstadt et al., 2013; Nesbit et al., 2013; Li et al.,
2014; Piret et al., 2016; Tenhola et al., 2016). The discovery of
activating germline mutations in the ubiquitously expressed G11
protein was surprising, especially since apart from hypocalcemia,
and small stature reported in two families, no other obvious
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phenotypes were found. Further, studies of these families and
identification of new families, possibly with novel mutations, will
increase our understanding of the action of Gα11 and refine the
phenotypic characteristics of patients with ADH2.
CONCLUSIONS AND UNANSWERED
QUESTIONS
In conclusion, much has been learnt from mutations in the
CASR and its signaling molecule G11. Activating mutations of
the CASR lead to ADH1 and activating mutations in Gα11
cause ADH2. Hypercalciuria is a particularly difficult problem
in ADH1 due to two independent mechanisms: low PTH and
activation of the CASR in the renal TAL. The use of small
molecule negative CASR modulators (calcilytics) for treatment
of ADH1 has the potential to correct defects both in the
parathyroid glands and in the renal tubule. In vitro studies and
experiments in mouse models of ADH1 have demonstrated the
ability of calcilytics to stimulate PTH, increase serum calcium,
and decrease urinary calcium. A preliminary report of a phase 2
clinical trial is consistent with the efficacy of calcilytics in ADH1
patients. Clearly, small molecule CASR inhibitors would be a
very attractive treatment option and in line with the concept of
“precision medicine” for patients with ADH1.
Many important questions about ADH1 and ADH2 remain
and further research is needed. Do patients with germline
activating mutations in Gα11 have other, perhaps more subtle
phenotypes caused by the activation of Gα11 in other tissues? Do
different mutations lead to different phenotypes? Do calcilytics
alleviate the biochemical abnormalities in vivo in patients with
Gα11 mutations? Is there a role for the recently described G11/q
inhibitors YM254890 and FR900359 (Schrage et al., 2015; Xiong
et al., 2016) as a treatment for ADH2? Could novel PTH agonists
be useful in the treatment of ADH (Bi et al., 2015)? Investigating
these questions could ultimately help define new drug targets
and improve medical management of patients with ADH types
1 and 2.
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